CARLSBAD, Calif., September 04, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, subst

Ionis Pharmaceuticals, Inc. faces significant setbacks after initial optimism, with shares dropping sharply from 52-week highs. Read more on IONS stock here.

Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene. The approval includes a bro

How to get additional patients diagnosed and hit the estimated peak sales of $100 million for Zanvastro (zilganersen) became the next project for Ionis Pharmaceuticals Inc. after the U.S. FDA cleared the antisense drug for Alexander disease in pediatric and adult patients, the first and only disease-modifying treatment for the ultra-rare, progressive and often fatal neurological disorder.

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.